Last update 04 Nov 2024
Butylphthalide
Last update 04 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms 3-n-butylphthalide, Butylphthalide and Sodium Chloride, 728 + [6] |
Target |
Mechanism KCNK inhibitors(Potassium two pore domain channel subfamily K inhibitors), Platelet aggregation inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (30 Sep 2002), |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC12H14O2 |
InChIKeyHJXMNVQARNZTEE-UHFFFAOYSA-N |
CAS Registry6066-49-5 |
Related
57
Clinical Trials associated with Butylphthalide丁苯酞氯化钠注射液人体生物等效性研究
[Translation] Study on the bioequivalence of sodium chloride butylphthalide injection in healthy volunteers
丁苯酞软胶囊在空腹条件下的人体生物等效性试验
[Translation] Bioequivalence study of butylphthalide soft capsules in humans under fasting conditions
丁苯酞软胶囊空腹人体生物等效性研究
[Translation] Study on the bioequivalence of butylphthalide soft capsules in fasting volunteers
100 Clinical Results associated with Butylphthalide
Login to view more data
100 Translational Medicine associated with Butylphthalide
Login to view more data
100 Patents (Medical) associated with Butylphthalide
Login to view more data
333
Literatures (Medical) associated with Butylphthalide01 Jan 2025JOURNAL OF ETHNOPHARMACOLOGY
Butylphthalide mitigates traumatic brain injury by activating anti-ferroptotic AHR-CYP1B1 pathway
Article
Author: Ni, Haoqi ; Chen, Zhibo ; Zhuge, Qichuan ; Qian, Wenqi ; Yang, Su ; Gu, Liuqing ; Ni, Zhihui ; Yan, Lin ; Yuan, Lin ; Lv, Xinhuang
ETHNOPHARMACOLOGICAL RELEVANCE:
Increasing evidence suggests that ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation, may play a substantial role in the traumatic brain injury (TBI) pathophysiology. 3-n-butylphthalide (NBP), a compound extracted from the seeds of Apium graveolens Linn (Chinese celery) and used in China to treat ischemic stroke, has demonstrated encouraging anti-reactive oxygen species (ROS) effects. Ascertaining whether NBP can inhibit ferroptosis and its mechanism could potentially expand its use in models of neurological injury and neurodegenerative diseases.
METHODS AND RESULTS:
In this study, we used erastin-induced in vitro ferroptosis models (HT22 cells, hippocampal slices, and primary neurons) and an in vivo controlled cortical impact mouse model. Our study revealed that NBP administration mitigated erastin-induced death in HT-22 cells and decreased ROS levels, lipid peroxidation, and mitochondrial superoxide indicators, resulting in mitochondrial protection. Moreover, the ability of NBP to inhibit ferroptosis was confirmed in organotypic hippocampal slice cultures and a TBI mouse model. NBP rescued neurons, inhibited microglial activation, and reduced iron levels in the brain tissue. The protective effect of NBP can be partly attributed to the inhibition of the AHR-CYP1B1 axis, as evidenced by RNA-seq and CYP1B1 overexpression/inhibition experiments in HT22 cells and primary neurons.
CONCLUSIONS:
Our study underscores that NBP inhibition of the AHR-CYP1B1 axis reduces ferroptosis in neuronal damage and ameliorates brain injury.
01 Oct 2024Neurotherapeutics
Cerebroprotective action of butylphthalide in acute ischemic stroke: Potential role of Nrf2/HO-1 signaling pathway
Article
Author: Chauhan, Anil K. ; Patel, Rakesh B. ; Patel, Rakesh B ; Chauhan, Anil K
24 Sep 2024ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
Influences of Butylphthalide Injection in Combination with Edaravone on Clinical Efficacy and Cytokines in Elderly Acute Cerebral Infarction Patients.
Article
Author: Guo, Lei ; Sun, Kunyu
Background:
Acute cerebral infarction threatens human health and life safety. The edaravone is a new antioxidant and hydroxyl radical scavenger, which is used in the treatment of cardiovascular diseases. However, long-term use of edaravone is prone to drug resistance, resulting in limited therapeutic effect. Butylphthalein can improve collateral circulation, protect the integrity of vascular endothelial cells, improve vasospasm, increase blood perfusion in the ischemic area of brain tissue, and promote the recovery of cerebral nerve function.
Objective:
To measure the influences of butylphthalide injection in combination with edaravone on clinical efficacy and cytokines in elderly acute cerebral infarction patients, aiming to provide reference for the treatment of acute cerebral infarction.
Design:
This was a retrospective study.
Setting:
This study was performed in Yantaishan Hospital.
Participants:
A total of 168 elderly acute cerebral infarction patients who accepted therapy in our hospital from February 2022 to February 2023 were chosen and allocated into a combination group and a control group.
Interventions:
The control group accepted the edaravone injection treatment. The combination group was treated with edaravone injection combined with butylphthalide injection.
Primary Outcome Measures:
(1) Therapeutic effect (2) Cytokines (3) Vascular endothelial function (4) Oxidative stress (5) Degree of neurological impairment (6) Living ability.
Results:
The total effective rate in the combination group presented elevation when in contrast to the control group (P < .05). After therapy, the levels of cytokines in the combination group presented reduction relative to the control group (P < .05), nitric oxide level in the combination group presented elevation when in contrast to the control group (P < .05), vascular endothelial growth factor level in the combination group presented lessened relative to the control group (P < .05), glutathione peroxidase along with superoxide dismutase levels in the combination group presented higher relative to the control group (P < .05) and malondialdehyde level in the combination group presented lower relative to the control group (P < .05). After therapy, the National Institute of Stroke Scale score in the combination group presented reduced when compared with the control group (P < .05). In contrast, the activity of daily living score in the combination group presented higher relative to the control group (P < .05).
Conclusion:
Butylphthalide injection in combination with edaravone can effectively inhibit the inflammatory response and oxidative stress, promote vascular endothelial function, improve daily behavior ability as well as promote the neurological function of elderly acute cerebral infarction patients.
100 Deals associated with Butylphthalide
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Butylphthalide |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Stroke | CN | 30 Sep 2002 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dementia, Vascular | Phase 3 | CN | 27 Nov 2019 | |
| Dementia, Vascular | Phase 3 | CN | 27 Nov 2019 | |
| Brain Ischemia | Phase 3 | CN | 01 Jul 2011 | |
| Ischemic stroke | Phase 2 | US | 15 Jul 2022 | |
| Peripheral Nerve Injuries | Phase 2 | CN | 30 Mar 2022 | |
| Peripheral Nerve Injuries | Phase 2 | CN | 30 Mar 2022 | |
| Acute Ischemic Stroke | Phase 1 | CN | 24 Aug 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 84 | (Dl-3-n-butylphthalide) | stsomifjkb(uqizwqhbpc) = lrqurzsdks xhyczmavmy (dbwuychupa, kwvlnrdbfr - tgdqxzuuhu) View more | - | 18 May 2016 | ||
(Cerebrolysin) | stsomifjkb(uqizwqhbpc) = uoubnnmnsn xhyczmavmy (dbwuychupa, luprwexwpa - bgbbpbvewn) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free